PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM) Stock Price, Analysis & Data
| Bid | 3.74 |
| Market Cap | 37.23M |
| Revenue (ttm) | 85K |
| Net Income (ttm) | -28.46M |
| Beta | 0.52 |
| EPS (ttm) | -48.31 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.12 |
| P/B (ttm) | 0.91 |
| P/S (ttm) | 437.96 |
| Earnings Date | Aug 14, 2026 |
| Ask | 5.5 |
| Volume | 26,964 |
| Avg. Volume (20D) | 27,908 |
| Open | 4.83 |
| Previous Close | 4.74 |
| Day's Range | 4.25 - 5.20 |
| 52-Week Range | 3.85 - 28.44 |
| Analyst | n/a |
| Price Target | 36 (592.31%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PAVM
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deat...
Financial Performance
In 2025, PAVmed's revenue was 71K, a decrease of -97.63% compared to the previous year's 3M. Earnings were 401K, a decrease of -98.99%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for PAVM stock is "null". The 12-month stock price forecast is 36, which is upside of 592.31% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
